214 related articles for article (PubMed ID: 19666776)
21. Update on Novel Targeted Therapy for Pleural Organization and Fibrosis.
Tucker TA; Idell S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163509
[TBL] [Abstract][Full Text] [Related]
22. Precision targeting of the plasminogen activator inhibitor-1 mechanism increases efficacy of fibrinolytic therapy in empyema.
Florova G; Girard RA; Azghani AO; Sarva K; Buchanan A; Karandashova S; DeVera CJ; Morris D; Chamiso M; Koenig K; Cines DB; Idell S; Komissarov AA
Physiol Rep; 2021 May; 9(9):e14861. PubMed ID: 33991465
[TBL] [Abstract][Full Text] [Related]
23. The fibrinolytic system: A new target for treatment of depression with psychedelics.
Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
[TBL] [Abstract][Full Text] [Related]
24. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Mutch NJ; Moore NR; Wang E; Booth NA
J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
[TBL] [Abstract][Full Text] [Related]
25. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
Behrendt N; List K; Andreasen PA; Danø K
Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
[TBL] [Abstract][Full Text] [Related]
26. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
[TBL] [Abstract][Full Text] [Related]
27. The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review.
Tucker TA; Idell S
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33535429
[TBL] [Abstract][Full Text] [Related]
28. Urokinase-type plasminogen activator (uPA) induces pulmonary microvascular endothelial permeability through low density lipoprotein receptor-related protein (LRP)-dependent activation of endothelial nitric-oxide synthase.
Makarova AM; Lebedeva TV; Nassar T; Higazi AA; Xue J; Carinato ME; Bdeir K; Cines DB; Stepanova V
J Biol Chem; 2011 Jul; 286(26):23044-53. PubMed ID: 21540184
[TBL] [Abstract][Full Text] [Related]
29. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Chang AW; Kuo A; Barnathan ES; Okada SS
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor.
Higazi A; Cohen RL; Henkin J; Kniss D; Schwartz BS; Cines DB
J Biol Chem; 1995 Jul; 270(29):17375-80. PubMed ID: 7615542
[TBL] [Abstract][Full Text] [Related]
31. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
32. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
Lockwood CJ; Krikun G; Aigner S; Schatz F
J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
[TBL] [Abstract][Full Text] [Related]
33. A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase.
Gong L; Proulle V; Fang C; Hong Z; Lin Z; Liu M; Xue G; Yuan C; Lin L; Furie B; Flaumenhaft R; Andreasen P; Furie B; Huang M
J Cell Mol Med; 2016 Oct; 20(10):1851-60. PubMed ID: 27197780
[TBL] [Abstract][Full Text] [Related]
34. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
35. Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.
Murciano JC; Higazi AA; Cines DB; Muzykantov VR
J Control Release; 2009 Nov; 139(3):190-6. PubMed ID: 19616049
[TBL] [Abstract][Full Text] [Related]
36. The circulatory regulation of TPA and UPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine.
Chandler WL; Levy WC; Stratton JR
Circulation; 1995 Nov; 92(10):2984-94. PubMed ID: 7586269
[TBL] [Abstract][Full Text] [Related]
37. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
[TBL] [Abstract][Full Text] [Related]
38. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
[TBL] [Abstract][Full Text] [Related]
39. Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
Bos R; Nieuwenhuizen W
Ann N Y Acad Sci; 1992 Dec; 667():428-30. PubMed ID: 1309066
[No Abstract] [Full Text] [Related]
40. Thrombospondin forms complexes with single-chain and two-chain forms of urokinase.
Silverstein RL; Nachman RL; Pannell R; Gurewich V; Harpel PC
J Biol Chem; 1990 Jul; 265(19):11289-94. PubMed ID: 2141608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
